Hemab is a clinical-stage biotech company developing next generation therapeutics for serious, underserved bleeding and thrombosis disorders. Based in Denmark and the US, Hemab aims to progress its pipeline of monoclonal and bispecific antibody-based therapeutics with the vision of transforming the treatment paradigm for patients with bleeding and thrombotic disorders with high unmet need. Learn more at hemab.com.